Affiliation:
1. University of Toronto
2. Unity Health Toronto
3. Meso Scale Discovery (United States)
4. University Health Network
5. Mount Sinai Hospital
Abstract
Abstract
Background
Certain demyelinating disorders, such as neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) exhibit serum autoantibodies against aquaporin-4 (αAQP4) and myelin oligodendrocyte glycoprotein (αMOG). The variability of the autoantibody presentation warrants further research into subtyping each case.
Methods
To elucidate the relationship between astroglial and neuronal protein concentrations in the peripheral circulation with occurrence of these autoantibodies, 86 serum samples were analyzed using immunoassays. The protein concentration of glial fibrillary acidic protein (GFAP), neurofilament light chain (NFL) and tau protein was measured in 3 groups of subcategories of suspected NMOSD: αAQP4 positive (n = 20), αMOG positive (n = 32) and αMOG/αAQP4 seronegative (n = 34). Kruskal-Wallis analysis, univariate predictor analysis, and multivariate logistic regression with ROC curves were performed.
Results
GFAP and NFL concentrations were significantly elevated in the αAQP4 positive group (p = 0.003; p = 0.042, respectively), and tau was elevated in the αMOG/αAQP4 seronegative group (p < 0.001). A logistic regression model to classify serostatus was able to separate αAQP4 seropositivity using GFAP + tau, and αMOG seropositivity using tau. The areas under the ROC curves (AUCs) were 0.77 and 0.72, respectively. Finally, a combined seropositivity versus negative status logistic regression model was generated, with AUC = 0.80.
Conclusion
The 3 markers can univariately and multivariately classify with moderate accuracy the samples with seropositivity and seronegativity for αAQP4 and αMOG.
Publisher
Research Square Platform LLC
Reference68 articles.
1. Cell locations for AQP1, AQP4 and 9 in the non-human primate brain;Arciénega II;Neuroscience,2010
2. Neuroimmunological Implications of AQP4 in Astrocytes;Ikeshima-Kataoka H;Int J Mol Sci,2016
3. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin;Jarius S;J Neuroinflammation,2016
4. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders;Wingerchuk DM;Neurology,2015
5. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis;Lennon VA;Lancet Lond Engl,2004